Supplement Figure S4 from Lipid Nanoparticle–Encapsulated mRNA-2752 Encoding Human OX40L, IL-23, and IL-36γ plus Durvalumab Induces an Immunostimulatory Effect within the Tumor Microenvironment in Patients with Advanced Solid Tumors

<jats:p>&lt;p&gt;Change in plasma IFN-γ and IL-23 cytokine and IL-23 mRNA concentration over time in (A) Arm A and (B) Arm B, and IL-23 and IFN-γ AUC at cycle 1 and cycle 2 in (C) Arm A and (D) Arm B, by dose of mRNA-2752. Panels A and C show the change in cytokine (IFN-γ and IL-23) and mRNA (IL-23) concentration (pg/mL) for each participant. Panels B and D show the cycle 1 and cycle 2 AUC of IFN-γ and IL-23 cytokines, where each dot is representative of an individual patient. For panels A and B, the IL-23 analyses dataset included 109 patients, and the IFN-γ analyses included 108 patients. AUC, area under the curve; IFN-γ, interferon gamma; IL, interleukin; mRNA, messenger RNA.&lt;/p&gt;</jats:p>